Full Press Release Details
• LinkedIn
• Facebook
• X (Twitter)
• Bluesky
• Threads
• Email
• Copy Link
The FDA has issued a complete response letter regarding Regeneron’s supplemental biologics license application for 12-week dosing of Eylea, the company announced in a press release.
The letter was issued because of “ongoing labeling discussions,” the release said.
The application was based on second-year data from the VIEW studies, in which patients with wet age-related macular degeneration received Eylea (aflibercept) injections at least every 12 weeks, with additional doses as needed, the release said.
The current recommended dose of Eylea for wet AMD is a 2-mg injection every 8 weeks after three initial monthly injections.
Final FDA action is expected within 2 months.
Ask a clinical question and tap into Healio AI's knowledge base.
• PubMed, enrolling/recruiting trials, guidelines
• Clinical Guidance, Healio CME, FDA news
• Healio's exclusive daily news coverage of clinical data